<DOC>
	<DOCNO>NCT00834301</DOCNO>
	<brief_summary>The purpose study determine whether ingestion new renal multivitamin supplement beneficial effect bone mineral adn inflammation issue relate patient dialysis .</brief_summary>
	<brief_title>An Open Label Trial Evaluate Effects Novel Renal Multivitamin Inflammation Other Biomarkers Endstage Renal Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>End stage renal disease patient dialysis least 90 day deem low risk investigator hospitalize concurrent infection Serum phosphorous level &gt; 5 mg/dl Stable phosphate binder regimen 2 week prior enrollment Stable dose Vitamin D 4 week prior enrollment Stable calcimimetic dose 4 week prior enrollment patient pregnant patient pre exist thrombocytopenia define platelet count &lt; 100 x 109/L abnormal LFTs baseline CRP &gt; 15 g/dl know sensitivity active ingredient patient currently enrol clinical trial , clinical trial last six month currently take immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Inflammation</keyword>
</DOC>